All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
How can we better treat patients with early-relapsing follicular lymphoma?
Bookmark this article
During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Emmanuel Bachy, Hospices Civils de Lyon, Lyon, FR. We asked, How can we better treat patients with early-relapsing follicular lymphoma?
How can we better treat patients with early-relapsing follicular lymphoma?
Emmanuel Bachy starts by stating that challenges remain in 2020 for treating patients with follicular lymphoma. Patients who relapse in the first 1–2 years after immunotherapy have a 5-year survival of only 40–50%. He goes on to discuss prognostic factors that are available both for prognosis and monitoring after treatment.
Bachy then turns his focus to therapeutic agents. The current available treatments are discussed, with respect to the age and frailty of the patients.
More about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
7 votes - 17 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox